Table 2.

Ongoing clinical trials of (neo)adjuvant immunotherapy for hepatocellular carcinoma (HCC).

ICI	Controls	Setting	Identifier (Name)	Phase
atezolizumab + bevacizumab	active surveillance	adjuvant after curative resection or ablation	NCT04102098 (IMbrave 050)	III
durvalumab ± bevacizumab	placebo	adjuvant after curative resection or ablation	NCT03847428 (EMERALD-2)	III
nivolumab	placebo	adjuvant after curative resection or ablation	NCT03383458 (CheckMate 9DX)	III
pembrolizumab	placebo	adjuvant after curative resection or ablation	NCT03867084 (KEYNOTE-937)	III
nivolumab ± ipilimumab	–	perioperative in (potentially) resectable HCC	NCT03222076	II
nivolumab + ipilimumab	–	neoadjuvant prior to resection	NCT03510871	II
nivolumab + ipilimumab	–	neoadjuvant prior to resection	NCT03682276 (PRIME-HCC)	I/II
nivolumab + cabozantinib	–	neoadjuvant prior to resection	NCT03299946	I